Showing results (561-570 of 611) with videos related to

Sort By:
Pageof 62
Frontiers in Immunology|May 27, 2022
Complement Factor I Variants in Complement-Mediated Renal DiseasesYuzhou Zhang, Renee X Goodfellow, Nicolo Ghiringhelli Borsa, et al.
Nucleic Acids Research|January 14, 2026
Visualization and quantification of rDNA instabilities in mammalian cells and mouse modelsXiaolu Zhu, Wenxia Jiang, Wei Wu, et al.
Frontiers in Synaptic Neuroscience|July 5, 2021
Maturation of Heterogeneity in Afferent Synapse Ultrastructure in the Mouse CochleaShelby A Payne, Matthew S Joens, Heather Chung, et al.
Prosthetics and Orthotics International|April 16, 2024
A scoping review of digital fabrication techniques applied to prosthetics and orthotics: Part 1 of 2-ProstheticsBen M Oldfrey, Dafne Z Morgado Ramirez, Mark Miodownik, et al.
Field Crops Research|March 18, 2024
Filling the agronomic data gap through a minimum data collection approachFatima A M Tenorio, Juan I Rattalino Edreira, Juan Pablo Monzon, et al.
Journal of Clinical Medicine|February 6, 2019
Confidence in Women's Health: A Cross Border Survey of Adult NephrologistsElizabeth M Hendren, Monica L Reynolds, Laura H Mariani, et al.
Kidney International Reports|February 24, 2025
Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 GlomerulopathyCarla M Nester, Ute Eisenberger, Alexandre Karras, et al.
Lancet (London, England)|September 28, 2025
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 studyDavid Kavanagh, Andrew S Bomback, Marina Vivarelli, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2026
Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis: Phase 3 VALIANT Subgroup AnalysisMarina Vivarelli, Gema Ariceta, Yael Borovitz, et al.
Pageof 62